Expression of mitofusin 2 in placentae of women with gestational diabetes mellitus
- 55 Downloads
Gestational diabetes mellitus (GDM) represents a common carbohydrate metabolism disorder during pregnancy. The objective of this study was to evaluate the expression levels of mitofusin 2 (MFN2) expression in placentae of GDM patients compared to that in the placental tissues from normal uncomplicated pregnancies. A total of 70 subjects were enrolled from September 2014 to June 2016, including 42 patients with GDM (the GDM group) and 28 normal uncomplicated pregnancies (the control group). Immunohistochemical staining and qRT-PCR were used for the detection of the expression levels and distribution of MFN2 in the placentae of GDM patients and normal controls. Kolmogorov–Smirnov test was used for statistical analysis. \(P<0.05\) and \(P<0.01\) were used for assessing statistical significance. The baseline characteristics were comparable in both groups. The 1-h and 2-h postprandial glucose levels (PPG) were \(7.94\pm 1.26\) versus \(6.88\pm 0.51\) mmol/L and \(7.01\pm 1.34\) versus \(6.14\pm 0.63\) mmol/L, respectively, for the GDM group and the control group (\(P<0.05\)). The relative expression levels of MFN2 mRNA were \(0.982\pm 1.242\) for GDM and \(1.257\pm 0.815\) for control, respectively, with significant between group difference (\(P<0.01\)). Immunohistochemical staining analysis showed that MFN2 was mostly distributed in the cytoplasm of syncytiotrophoblasts under optical microscopy. Additionally, about 50% of samples of the GDM group were within the intensity of moderate staining of MFN2 and more than 50% of patients in the control group were within the intensity of strong staining of MFN2. The expression levels of MFN2 in GDM placentae was significantly lower compared to that of placentae from normal uncomplicated pregnancies.
Keywordsgestational diabetes mellitus placenta mitofusin 2 immunohistochemical staining
This work was supported by the Minhang District Natural Science Foundation of Shanghai (programme no. 2015MHZ014).
- Enquobahrie D. A., Williams M. A., Qiu C., Meller M. and Sorensen T. K. 2009 Global placental gene expression in gestational diabetes mellitus. Am. J. Obstet. Gynecol. 200, 206. e201–206. e213.Google Scholar
- Fernandez-Morera J., Rodriguez-Rodero S., Menendez-Torre E. and Fraga M. 2010 The possible role of epigenetics in gestational diabetes: cause, consequence, or both. Obstet. Gynecol. Int. 2010, article ID 605163.Google Scholar
- Pang W.-J., Zhao N. and Fu X.-C. 2011 Expression of mitofusin 2 in villous tissue of cases with missed abortion. Matern. Child Health Care China 33, 048.Google Scholar
- Rani P. R. and BeGuM J. 2016 Screening and diagnosis of gestational diabetes mellitus, where do we stand. J. Clin. diagn. Res., JCDR. 10, QE01.Google Scholar
- Rojas J., Chávez-Castillo M. and Bermúdez V. 2014 The role of metformin in metabolic disturbances during pregnancy: polycystic ovary syndrome and gestational diabetes mellitus. Int. J. Reprod. Med. 2014, article ID 797681.Google Scholar
- Rosenstein M. G., Cheng Y. W., Snowden J. M., Nicholson J. M., Doss A. E. and Caughey A. B. 2012 The risk of stillbirth and infant death stratified by gestational age in women with gestational diabetes. Am. J. Obstet. Gynecol. 206, 309. e301–309. e307.Google Scholar